Candesartan cilexetil
Key facts
| Invented name |
Atacand and associated name
|
| Active substance |
Candesartan cilexetil
|
| Therapeutic area |
Cardiovascular diseases
|
| Decision number |
P/21/2009
|
| PIP number |
Candesartan cilexetil
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
AstraZeneca AB
E-mail: paediatrics@astrazeneca.com |
| Decision type |
RP: decision refers to a refusal on a proposed Paediatric Investigation Plan
|